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Abstract Several acutely acting antimigraine drugs, includ-
ing ergotamine and sumatriptan, have the ability to constrict
porcine arteriovenous anastomoses as well as the human iso-
lated coronary artery. These two experimental models seem
to serve as indicators, respectively, for the therapeutic and
coronary side-effect potential of the compounds. Using
these two models, we have now investigated the effects of
avitriptan (BMS-180048; 3-[3-[4-(5-methoxy-4-pyrimidi-
nyl)-1-piperazinyl]propyl]-N-methyl-1H-indole-5-methane-
sulfonamide monofumarate), a new 5-HT1B/1D receptor ago-
nist. In anaesthetized pigs, avitriptan (10, 30, 100 and
300 lg·kg–1) decreased the total carotid blood flow by ex-
clusively decreasing arteriovenous anastomotic blood flow;
capillary blood flow was increased. The mean ± SEM i.v.
dose of avitriptan eliciting a 50% decrease (ED50) in the por-
cine carotid arteriovenous anastomotic blood flow was cal-
culated to be 76 ± 23 lg·kg–1 (132 ± 40 nmol·kg–1) and
the highest dose (300 lg·kg–1) produced a 72 ± 4% reduc-
tion. In recent comparative experiments (DeVries et al.
1996), the mean ± SEM ED50 (i.v.) of sumatriptan in de-
creasing carotid arteriovenous anastomotic blood flow was
63 ± 17 lg·kg–1 (158 ± 43 nmol·kg–1), with a reduction of
76 ± 4% by 300 lg·kg–1, i.v. Both avitriptan (pD2:
7.39 ± 0.09; Emax: 13.0 ± 4.5% of the contraction to
100 mM K+) and sumatriptan (pD2: 6.33 ± 0.09; Emax:
15.5 ± 2.3% of the contraction to 100 mM K+) contracted
the human isolated coronary artery. The above results sug-
gest that avitriptan should be able to abort migraine head-
aches in patients, but may exhibit sumatriptan-like effects
on coronary arteries. Initial clinical studies have demon-
strated the therapeutic action of the drug in acute migraine.
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Introduction
Sumatriptan, which is the first member of a completely
new class of compounds designated as 5-HT1-like (or 5-
HT1D) receptor agonists (Humphrey et al. 1988, 1990;
Saxena and Ferrari 1992), is very effective in aborting mi-
graine headaches (The Subcutaneous Sumatriptan Interna-
tional Study Group 1991; Ferrari and Saxena 1993). The
drug constricts large cranial and extracranial blood vessels
(see Saxena and Tfelt-Hansen 1993), including porcine
carotid arteriovenous anastomoses (Den Boer et al. 1991a,
1992) and the vasoconstrictor effects, susceptible to
methiothepin but not to ketanserin, are mediated via the 5-
HT1-like receptor (Humphrey et al. 1988, 1990; Saxena et
al. 1986; Hoyer et al. 1994). Evidence is now emerging
that the vascular 5-HT1-like receptor may be identical to
the recombinant 5-HT1B/1D (formerly designated as 5-
HT1Db and 5-HT1Da, respectively; see Hartig et al. 1996)
receptors, but most probably the 5-HT1B receptor. Thus,
the mRNA for the 5-HT1B, but not that for 5-HT1D, recep-
tor is present in cranial blood vessels (Hamel et al. 1993)
and the vasoconstrictor effect of sumatriptan, which has a
high affinity for 5-HT1B/1D receptors (Peroutka and Mac-
Carthy 1989; Beattie et al. 1994), is antagonized by
GR127935, a selective 5-HT1B/1D receptor antagonist
(Skingle et al. 1993; Clitherow et al. 1994; De Vries et al.
1996).
The introduction of sumatriptan in migraine therapy has
prompted several pharmaceutical companies to synthesize
and evaluate new compounds with binding affinity and po-
tential agonist activity at 5-HT1B/1D receptors (for a re-
view, see Saxena and Ferrari 1996). One such compound
currently undergoing clinical evaluation is avitriptan
(BMS-180048), which is a methoxypyrimidinyl-piperazi-
nyl analogue of sumatriptan, synthesized by Bristol-Myers
Squibb, Wallingford, CT, USA (Fig. 1). The binding pro-
file of avitriptan is comparable to that of sumatriptan and
avitriptan also has a selective affinity for 5-HT1B/1D recep-
tors, without distinguishing between the 5-HT1B and 5-
HT1D subtypes (Table 1; Yocca et al. 1995). In the present
investigation, we have studied the effects of avitriptan in
experimental models predictive of therapeutic activity in
migraine (constriction of carotid arteriovenous anasto-
moses in anaesthetized pigs; Saxena 1990, 1995) and co-
ronary side effects (constriction of human isolated coron-
ary artery; Connor et al. 1989; Chester et al. 1990; Bax et
al. 1993; Bax and Saxena 1993). In the latter model, su-
matriptan was simultaneously used for a direct compari-
son, whereas data obtained in the first model was com-
pared with that obtained with sumatriptan in a series of ex-
periments (De Vries et al. 1996) performed around the
same time.
Materials and methods
Systemic and carotid haemodynamics in anaesthetized pigs
General. After an overnight fast, 14 pigs (Yorkshire · Landrace; 10-
15 kg) were anaesthetized with azaperone (160 mg, i.m.), midazolan
hydrochloride (5 mg, i.m.) and metomidate (200 mg, i.v.), intubated
and connected to a respirator (BEAR 2E, BeMeds AG, Baar, Switzer-
land) for intermittent positive pressure ventilation with a mixture of
room air and oxygen. Respiratory rate, tidal volume and oxygen sup-
ply were adjusted to keep arterial blood gas values within physiologi-
cal limits (pH: 7.35–7.48; pCO2: 35–48 mmHg; pO2: 100–120
mmHg). Anaesthesia was maintained with a continuous i.v. infusion
of pentobarbitone sodium at 20 mg·kg–1·h–1. With this anaesthetic re-
gimen, arteriovenous anastomotic blood flow is considerably higher
than that in pigs in a conscious state or under thiopentone anaesthesia
(Den Boer et al. 1993).
Catheters were placed in the inferior vena cava via the left femo-
ral vein for the administration of drugs and in the aortic arch via the
left femoral artery for the measurement of arterial blood pressure
(P23 Dc pressure transducer; Statham, Hato Rey, Puerto Rico) and
the withdrawal of arterial blood for determining blood gases (ABL-
510, Radiometer, Copenhagen, Denmark). The common carotid ar-
teries, external jugular veins and vagus nerves were identified and
both vagi and the accompanying cervical sympathetic nerves were cut
between two ligatures. Another catheter was placed in the right exter-
nal jugular vein for the withdrawal of venous blood samples, while
the right common carotid artery was dissected free and a needle was
inserted against the direction of blood flow for the administration and
uniform mixing of radioactive microspheres. Blood flow was mea-
sured in the right common carotid artery with a flow probe (internal
diameter: 2.5 mm) connected to a sine-wave electromagnetic flow
meter (Transflow 601-system, Skalar, Delft, The Netherlands). Heart
rate was measured with a tachograph (7P4 Grass Instrument Com-
pany, Quincy, Mass., USA) triggered by ECG signals.
Arterial blood pressure, heart rate and carotid blood flow were
continuously monitored on a model 7 Grass polygraph. Body tem-
perature was kept at about 378C and the animals were continuously
infused with saline to compensate for fluid losses during the experi-
ment.
Distribution of carotid blood flow. The distribution of common caro-
tid blood flow was determined with 15 ± 1 (S.D.) lm diameter mi-
crospheres labelled with either 141Ce, 113Sn, 95Nb, 103Ru or 46Sc
(NEN Company, Dreieich, Germany). For each measurement a sus-
pension of about 200000 microspheres, labelled with one of the iso-
topes, was mixed and injected into the carotid artery. At the end of
the experiment, the animal was killed and the heart, kidneys, lungs
and the different cranial tissues were dissected out, weighed and put
in vials. The radioactivity in these vials was counted for 5–10 min in
a c-scintillation counter (Packard, Minaxi autogamma 5000), using
suitable windows for discriminating the different isotopes. All data
were processed by a set of specially designed programs (Saxena et al.
1980), using a personal computer.
The fraction of carotid blood flow distributed to the different tis-
sues was calculated by multiplying the ratio of tissue and total radio-
activities by the total common carotid blood flow at the time of the
injection of microspheres. Since little or no radioactivity was detected
in the heart and kidneys, all microspheres trapped in lungs reached
this tissue from the venous side after escaping via carotid arteriove-
nous anastomoses. Therefore, the amount of radioactivity in the lungs
was used as an index of the arteriovenous anastomotic fraction of car-
otid blood flow (Johnston and Saxena 1978; Saxena and Verdouw
1982).
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Table 1 Binding affinities (pKi
values) of avitriptan and suma-
triptan at 5-HT receptors
5-HT1A 5-HT1B 5-HT1B 5-HT1D 5-HT2 5-HT3
Rat Rat Human Human Rat Rat
Avitriptan 7.15 7.44 7.68 8.36 5.68 <6.0
Sumatriptan 7.00 7.57 7.54 8.14 <5.0 <5.0
Data from Yocca et al. (1995) and Bristol-Myers Squibb files, except for sumatriptan on rat receptors
(Peroutka and MacCarthy 1989)
Fig. 1 Chemical structures of avitriptan and sumatriptan
Experimental protocol. The experiments were started after a stabiliza-
tion period of about 1 h and baseline values of heart rate, mean arteri-
al blood pressure, carotid blood flow and its distribution as well as ar-
terial and jugular venous blood gases were measured. The animals
were then divided into two groups receiving slow i.v. injections of
either avitriptan (cumulative doses: 10, 30, 100 and 300 lg·kg–1;
n = 7) or physiologic saline (0.5, 1, 2 and 4 ml; n = 7) over a 3–
4 min period. The variables were reassessed about ten min after the
end of each injection.
Human isolated coronary artery
Tissue preparation. As described previously (Bax et al. 1993), the
right epicardial coronary artery was obtained (via the Rotterdam Heart
Valve Bank, Bio Implant Services/Eurotransplant Foundation) from 7
heart beating organ donors, who died of non-cardiac disorders (3
cerebrovascular accident, 2 head trauma, 2 cerebral hypoxia; 4 male,
3 female; age 1-53 years with mean ± SEM 37.4 ± 6.7 years) less
than 24 h before the tissue was brought to the laboratory. The hearts
were stored at 0–48C in a sterile organ protecting solution (UW, Euro-
Collins or HTK-Brettschneider; see Ploeg et al. 1992) immediately
following circulatory arrest. After arrival in the laboratory, the right
coronary artery was removed and placed in a cold, oxygenated Krebs
bicarbonate solution of the following composition: NaCl 118 mM,
KCl 4.7 mM, CaCl2 2.5 mM, MgSO4 1.2 mM, KH2PO4 1.2 mM,
NaHCO2 25 mM and glucose 8.3 mM; pH 7.4. The vessel was cut
into rings of approximately 4 mm of length and suspended on stain-
less steel hooks in 15 ml organ baths containing the Krebs bicarbo-
nate solution, aerated with 95% O2 and 5% CO2 and maintained at
378C. Vessel segments containing macroscopically visible athero-
sclerotic lesions were not used in the present study. The segments
were allowed to equilibrate for at least 30 min and washed every
15 min. Changes in tension were recorded using a Harvard isometric
transducer. Preparations were stretched to a stable pre-tension of
20 mN. The tissue was exposed to K+ (30 mM) twice. Subsequently,
the functional integrity of the endothelium was verified by observing
relaxation to substance P (1 nM) after precontraction with prostaglan-
din F2a (PGF2a, 1 lM). After washout, the tissue was exposed to K+
100 mM to determine the maximal contractile response to K+. The
tissue was then allowed to equilibrate in the Krebs solution for a
further 30 min.
Determination of agonist potency. After equilibration, a cumulative
concentration response curve was obtained with either avitriptan or
sumatriptan. The responses were expressed as increase of tension
(mN) as well as percentage of K+ (100 mM)-induced contractions.
Curves were obtained in a paired, parallel experimental set-up.
Where more vessel segments from one heart donor were used for
avitriptan or sumatriptan, the curves were averaged for the agonist
tested and considered in further analysis as one curve. Curves cover-
ing the full sigmoidal range were analysed by means of a computer-
ized curve fitting technique (DeLean et al. 1978) to obtain Emax
(maximal response) and pD2 (negative logarithm of the molar concen-
tration of an agonist needed to reach half of its Emax, i.e. -log EC50)
values, which were averaged for the respective agonists.
Ethical approval
The protocols for the two parts of the investigation were approved by
the joint Ethical Committees of the Erasmus University Rotterdam
and the University Hospital Rotterdam ‘Dijkzigt‘, dealing with the
use of animals and humans in scientific experiments.
Data presentation and statistical analysis
All data have been expressed as means ± SEM. In the haemodynamic
study, the significance of the changes (from baseline values) induced
by the different doses of avitriptan (or vehicle) was evaluated with
Duncan‘s new multiple range test, once an analysis of variance (ran-
domized block design) had revealed that the samples represented dif-
ferent populations. The changes caused by avitriptan (10, 30, 100 or
300 lg·kg–1) were compared with those in the vehicle group by using
Student‘s unpaired t-test. The dose of avitriptan eliciting a 50% de-
crease (ED50) in arteriovenous anastomotic blood flow was calculated
using linear regression analysis. In the isolated coronary artery stud-
ies, the significance of difference between the Emax and pD2 values of
sumatriptan and avitriptan was calculated by Student‘s paired t-test.
Statistical significance was accepted at P<0.05 (two-tailed).
Compounds
Apart from the anaesthetics, azaperone, metomidate (both from Jans-
sen Pharmaceutica, Beerse, Belgium), midazolan hydrochloride
(Hoffmann La Roche b.v., Mijdrecht, The Netherlands) and pentobar-
bitone sodium (Apharmo, Arnhem, The Netherlands), the compounds
used in this study were: prostaglandin F2a (Tris salt) and substance P
acetate (both purchased from Sigma Chemical Co., St. Louis, Mo.,
USA); sumatriptan succinate (Glaxo Group Research, Ware, Herts,
UK), avitriptan (BMS-180048; 3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-
piperazinyl]propyl]-N-methyl-1H-indole-5-methanesulfonamide mono-
fumarate; Bristol-Myers Squibb, Wallingford, Conn., USA) and hepar-
in sodium (Leo Pharmaceutical Products, Weesp, The Netherlands) to
prevent clotting of the catheters. For in vitro experiments, all com-
pounds (substance P, prostaglandin F2a, sumatriptan and avitriptan)
were dissolved in distilled water, while for in vivo experiments avi-
triptan was dissolved in physiological saline and all doses refer to the
salt.
Results
Systemic and carotid haemodynamics in anaesthetized pigs
Systemic haemodynamics
Heart rate decreased moderately, but significantly, in pigs
treated with the highest 3 doses of either physiological saline
(1, 2 and 4 ml) or avitriptan (30, 100 and 300 lg·kg–1, i.v.).
However, the decrease in heart rate with avitriptan was sig-
nificantly more than that with the corresponding dose of saline
(Table 2). Mean arterial blood pressure decreased slightly in
both saline (highest 2 doses) and avitriptan (highest dose)
groups. The change in the mean arterial blood pressure with
avitriptan was not significantly different from that in the saline
group (Table 2).
Arterio-jugular venous oxygen saturation difference
Avitriptan elicited an increase in the arterio-jugular venous
oxygen saturation difference with the two highest doses
(Table 2).
Carotid haemodynamics
The total carotid blood flow and its arteriovenous anasto-
motic fraction were significantly decreased by the 3 high-
est doses of avitriptan; the capillary fraction increased sig-
nificantly with the 2 highest doses. Treatment with physio-
logical saline did not produce any significant change in
the distribution of carotid blood flow (Fig. 2).
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Figure 3 presents the % changes produced by the dif-
ferent doses of avitriptan (upper panels) in the carotid
blood flow and its distribution into arteriovenous anasto-
motic and capillary fractions; the changes observed with
sumatriptan in recent experiments using the same experi-
mental model (data from De Vries et al. 1996; lower pa-
nels) are presented for comparison. The ED50 of avitriptan
in decreasing arteriovenous anastomotic blood flow was
calculated to be 76 ± 23 lg·kg–1 (132 ± 40 nmol·kg–1)
and with the highest dose (300 lg·kg–1) the decrease
amounted to be 72 ± 4%. Sumatriptan also decreased the
total carotid and arteriovenous anastomotic blood flows,
but the increase in the capillary blood flow was not statis-
tically significant (De Vries et al. 1996). The ED50 of su-
matriptan in decreasing arteriovenous anastomotic blood
flow was 63 ± 17 lg·kg–1 (158 ± 43 nmol·kg–1) and the
highest dose used (300 lg·kg–1) decreased arteriovenous
anastomotic blood flow by 76 ± 4%. Thus, the two com-
pounds, avitriptan and sumatriptan were both equipotent
and equi-effective in decreasing porcine carotid arteriove-
nous anastomotic blood flow.
The changes in the distribution of carotid blood flow to
the head tissues by avitriptan are depicted in Fig. 4. Avi-
triptan (‡ 100 lg·kg–1) increased the fraction of carotid
blood flow distributed to the skin, brain, ears, fat, muscles,
bones and salivary glands; the fraction distributed to the
eye did not change significantly.
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Table 2 Absolute values of
heart rate, mean arterial blood
pressure and difference in arterial
and jugular venous oxygen
saturation at baseline and after
cumulative doses of avitriptan
(n = 7) and its vehicle (physio-
logical saline; n = 7). Percent
changes from baseline in each
variable is given in brackets
Pretreatment Avitriptan (lg kg–1)
Baseline 10 30 100 300
Heart rate (beats min–1)
Saline (control)a 84±3 83±3 (–2±1) 81±3 (–4±1)b 80±3 (–5±2)b 78±3 (–7±2)b
Avitriptan 90±4 85±5 (–6±2) 79±5 (–12±3)b, c 77±5 (–14±4)b, c 75±5 (–17±4)b, c
Mean arterial blood pressure (mmHg)
Saline 98±6 95±6 (–3±1) 94±5 (–4±2) 88±7 (–11±4)b 86±7 (–13±3)b
Avitriptan 93±5 91±4 (–2±2) 90±5 (–2±4) 88±5 (–4±6) 80±5 (–13±6)b
Arteriovenous difference in oxygen saturation (%)
Saline 6.7±1.3 7.5±2.0 (4±12) 7.0±1.7 (3±12) 7.9±1.9 (23±23) 9.2±1.7 (52±24)
Avitriptan 4.4±0.5 5.1±1.2 (19±31) 6.9±1.1 (62±27) 9.5±1.9 (122±51)b 12.5±2.5 (182±70)b
All values are presented as means ± SEM. a The doses of saline, corresponding to avitriptan doses, were
0.5, 1, 2 and 4 ml. b Significant difference (P<0.05) from the baseline value; c % change from baseline
significantly different (P<0.05) from that in the saline group
Fig. 2 Effect of avitriptan
(upper panels) and physiological
saline (lower panels) on the total
carotid blood flow and its arter-
iovenous anastomotic (AVAs)
and nutrient (capillary) fractions
in anaesthetized pigs. All values
are presented as means ± SEM
*, P<0.05 vs baseline
Human isolated coronary artery
Effect of substance P and K+
Coronary vessel segments relaxed to substance P (1 nM)
after precontraction with PGF2a (1 lM) with 82.5 ± 9.8%
of the contractile responses to PGF2a. K+ (100 mM)
caused a mean contractile response of 40.9 ± 7.4 mN.
Effect of sumatriptan and avitriptan
As shown in Fig. 5, the human isolated coronary artery
contracted in a concentration-dependent manner to both
sumatriptan (pD2: 6.33 ± 0.09; Emax: 5.5 ± 1.0 mN or
15.5 ± 3.9% of contractions to 100 mM K+) and avitriptan
(pD2: 7.39 ± 0.09; Emax: 5.0 ± 1.9 mN or 13.0 ± 4.5% of
contractions to 100 mM K+). The pD2 of avitriptan was
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Fig. 3 Percent changes from
baseline values by avitriptan
(upper panels) in the total caro-
tid blood flow and its arteriove-
nous anastomotic (AVAs) and
nutrient (capillary) fractions in
anaesthetized pigs. For compari-
son, data of sumatriptan (lower
panels; n = 5), obtained in a re-
cent investigation (De Vries et al.
1996), have been included. All
values are presented as means ±
SEM *, P<0.05 vs baseline
Fig. 4 Effect of avitriptan on
the distribution of carotid blood
flow to different cranial tissues
in anaesthetized pigs. All values
are presented as means ± SEM,
*P<0.05 vs baseline
significantly higher than that of sumatriptan, but the Emax
of the two drugs did not differ significantly. Both drugs
appeared to elicit contractions at the same pace.
Discussion
Systemic haemodynamic changes
Although in the control (saline) experiments heart rate was
decreased, the decreases in heart rate by avitriptan
(–12 ± 3%, –14 ± 4 and –17 ± 4% after 30, 100 and
300 lg·kg–1, respectively) were more than in saline experi-
ments. A similar bradycardic effect has also been noticed
with sumatriptan (Feniuk et al. 1989; Den Boer et al.
1991a, 1992; DeVries et al. 1996). The mechanism in-
volved in the decrease in heart rate by sumatriptan or avi-
triptan is not clear, but it may be related to presynaptic in-
hibition of sympathetic neurons (Humphrey et al. 1988,
1990) or central 5-HT1A receptor activation (Dreteler et al.
1989; Saxena and Villalo´n 1990; see Table 1). However,
in any case, bradycardia following the use of sumatriptan
in patients seems to be of little clinical relevance (Saxena
and Tfelt-Hansen 1993) and the same seems to be true for
avitriptan, which is undergoing clinical trials (Goldstein
1995).
Significantly, the fact that avitriptan did not produce
changes in mean arterial blood pressure implies that, like
sumatriptan (Humphrey et al. 1988, 1990; Den Boer et al.
1991a), the drug has a more selective vasoconstrictor ac-
tion on cranial blood vessels than ergotamine, which eli-
cits a hypertensive response (Saxena and DeVlaam-Schlu-
ter 1974; Den Boer et al. 1991b).
Carotid haemodynamic changes
In the past we have reported that no significant changes in
the carotid haemodynamics are observed after treatment
with saline (e.g. Saxena and Verdouw 1982; Den Boer et
al. 1991a). The same was the case in the present experi-
ments with saline (see Fig. 2). On the other hand, like su-
matriptan (Perren et al. 1989; Den Boer et al. 1991a; De
Vries et al. 1996), avitriptan elicited a reduction in the to-
tal carotid blood flow, which was exclusively due to the
decrease in its arteriovenous anastomotic fraction; the ca-
pillary fraction distributed to several head tissues in fact
increased slightly. In conformity with the reduction of ar-
teriovenous anastomotic blood flow, avitriptan signifi-
cantly increased the arterio-jugular venous oxygen satura-
tion difference with the 2 highest doses. The vasoconstric-
tor effect of avitriptan on porcine carotid arteriovenous
anastomoses were similar to those observed with sumatrip-
tan in the same experimental model (Fig. 3; Den Boer et
al. 1991a; De Vries et al. 1996); the ED50 values
(132 ± 40 and 158 ± 43 nmol·kg–1, i.v., respectively) and
the maximal decreases (72 ± 4 and 76 ± 4%, respectively,
with 300 lg·kg–1, i.v.) in the case of the two drugs were
close to each other.
Although we have made no attempt to analyse the
mechanism of action involved in the porcine carotid vas-
cular changes by avitriptan, it is reasonable to expect that,
as in the case of sumatriptan (Saxena et al. 1986; De Vries
et al. 1996), 5-HT1B/1D receptors may mediate the re-
sponses to avitriptan; indeed, avitriptan has a similar affin-
ity as sumatriptan for human 5-HT1B and 5-HT1D recep-
tors (see Table 1). Furthermore, this compound is more po-
tent (2.5–7 times) than sumatriptan in constricting bovine
middle cerebral artery (pD2: 6.72 vs. 6.17; Emax: 44 vs.
50% of the response to 5-HT) and guinea-pig iliac artery
(pD2: 7.83 vs. 6.96; Emax: 58 vs. 74% of the response to
5-HT) and these effects of avitriptan are amenable to
blockade by methiothepin, but not ketanserin (Goggins et
al. 1996; Unpublished data on Bristol-Myers Squibb files).
Human isolated coronary artery
Sumatriptan has been reported to constrict the human cor-
onary artery, both in vivo (MacIntyre et al. 1993) and in
vitro (Connor et al. 1989; Chester et al. 1990; Bax et al.
1993; Bax and Saxena 1993). In the present experiments
with the human isolated coronary, avitriptan also showed a
contractile effect with a pD2 of 7.39 ± 0.09. As in the
other vascular reparations containing 5-HT1-like (5-HT1B/
1D) receptors in vitro (see above), avitriptan was 11 times
more potent in the human isolated coronary artery than su-
matriptan (pD2: 6.33 ± 0.09). It is known that the suma-
triptan-induced contractions of the human isolated coron-
ary artery are mediated by 5-HT1-like receptors (Connor et
al. 1989; Bax et al. 1993), which may resemble the 5-
HT1B receptor subtype (Kaumann et al. 1994). Since the
pKi values of avitriptan and sumatriptan at the human 5-
HT1B receptor (7.68 and 7.54, respectively) are similar, the
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Fig. 5 Human isolated coronary artery. Contractile responses to su-
matriptan (8 segments from 7 donors) and avitriptan (11 segments
from the same 7 donors), expressed both in mN (left panel) and as %
of the response to 100 mM K+ (right panel)
11-fold difference in the potency of the two compounds
(using a paired, parallel experimental design; see methods)
suggests that, apart from the 5-HT1B receptor, other 5-HT
receptors (5-HT1D, 5-ht1F?) probably also participate in
mediating the contraction of the human coronary artery.
An analysis of this response using newer 5-HT receptor li-
gands may shed further light into the receptor mechanisms
involved.
Clinical perspectives
Over the years it has been shown that a number of drugs
effective in aborting migraine headaches, including the er-
got alkaloids, ergotamine and dihydroergotamine (Johnston
and Saxena 1978; Schamhardt et al. 1979; Spierings and
Saxena 1980; Den Boer et al. 1991b), sumatriptan (Den
Boer et al. 1991a) as well as a number of second genera-
tion 5-HT1B/1D receptor agonists undergoing clinical evalu-
ation in migraine (e.g., zolmitriptan, rizatriptan and avitrip-
tan; Boulanger et al. 1995; Martin and Dixon 1995; Saxe-
na and Ferrari 1996), are able to constrict carotid arterio-
venous anastomoses, which may open up during the head-
ache phase of migraine (see Heyck 1969; Saxena 1990,
1995; Ferrari and Saxena 1993). Since avitriptan con-
stricted carotid arteriovenous anastomoses, it is suggested
that avitriptan should also be effective in aborting head-
aches in migraine patients. Preliminary clinical findings in-
deed seem to confirm this (Goldstein et al. 1996). The re-
sults obtained in the human isolated coronary artery, how-
ever, also suggest that, like sumatriptan, avitriptan may be
contra-indicated in patients with coronary artery disease.
Lastly, it may be remarked that although the experi-
mental models that we have used seem to be predictive of
therapeutic activity in migraine patients (porcine arteriove-
nous anastomotic constriction) as well as the coronary
side-effect liability (human isolated coronary artery con-
traction), we cannot directly calculate and compare the
‘therapeutic window’ of potential antimigraine drugs in
precise quantitative terms. As is quite obvious, the drug
dosage, efficacy and tolerability in patients will depend on
a host of factors, including the pharmacokinetic parameters
(oral absorption, tissue distribution, metabolic disposition
and plasma half-life), precise nature of receptors involved,
severity of migraine and presence of concomitant disease
processes.
In conclusion, the results of the present experiments
show that avitriptan, a 5-HT1B/1D receptor agonist, causes
constriction of porcine carotid arteriovenous anastomoses
(suggestive of therapeutic activity in migraine) and the hu-
man isolated coronary artery (possibly indicative of coron-
ary side-effects). Both these pharmacological effects are
broadly similar to those of sumatriptan.
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